Document is current
Any future updates will be listed below
-
Authors
Shi, Yuankai
Wang, Xinshuai
Pei, Zhidong
Shi, Huaqiu
Zhang, Yanjun
Yi, Tienan
Mei, Jiazhuan
Guo, Yanzhen
Dong, Youhong
Ma, Tianjiang
Zhang, Qingyuan
Jia, Xiaojing
Zhu, Zhengqiu
Xu, Shen
Liu, Yanyan
Niu, Hongrui
Jiang, Weimei
Jiang, Xiaodong
Zhou, Shengyu
Sun, Li
-
Funding
Funding for this research was provided by:
Xiamen Amoytop Biotech Co., LTD
- License Information
-
More Information
Article History
Received: 7 November 2024
Accepted: 14 February 2025
First Online: 17 March 2025
Declarations
:
: This study was approved by ethics committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and all the participating hospitals. This study was conducted in accordance with the International Council for Harmonization guidelines on Good Clinical Practice, China’s regulatory requirements and the ethical principles of Declaration of Helsinki. Written informed consents were obtained from all patients before study enrolment. This study was registered at ClinicalTrials.gov, number: NCT04466137.
: Not applicable.
: Li Sun is the employee of Xiamen Amoytop Biotech Co., LTD. All other authors declared no related conflict of interest.
